Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Haleon launches £330m share buyback programme

(Sharecast News) - Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated for repurchases in 2025. The FTSE 100 consumer products giant said the initiative followed its £170m off-market share purchase from Pfizer earlier in the month.

It said the first tranche of the buyback would total up to £200m, and will run until no later than 26 June.

Shares repurchased under the tranche would be cancelled, reducing Haleon's share capital.

The company said it expected the programme to enhance earnings per share, and align it with its broader capital allocation priorities including delivering shareholder returns.

Haleon said it had entered into an irrevocable agreement with Goldman Sachs International to execute the first tranche.

Goldman Sachs would carry out the purchases independently on the London Stock Exchange, including during any closed periods.

Further tranches would be announced in due course.

At 0815 GMT, shares in Haleon were up 0.81% at 385p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.